Fulgent Genetics Inc (OQ:FLGT)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
 
See Regulatory Filings on SEC
Company Contact
Address: 4978 Santa Anita Ave Ste 205
TEMPLE CITY CA 91780-3600
Tel: 1-415-2172633
Website: https://www.fulgentgenetics.com
IR: See website
<
Key People
Ming Hsieh
Chairman of the Board, President, Chief Executive Officer
Paul Kim
Chief Financial Officer
Jian Xie
Chief Operating Officer
Han Lin Gao
Chief Scientific Officer, Laboratory Director
   
Business Overview
Fulgent Genetics, Inc. is a technology company, which offers COVID-19 testing services, molecular diagnostic testing services and comprehensive genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the patient care quality. The Company develops a technology platform, which offers a test menu. It performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. It also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.
Financial Overview
For the nine months ended 30 September 2022, Fulgent Genetics Inc revenues decreased 26% to $551.3M. Net income decreased 59% to $167.2M. Revenues reflect Insurance segment decrease of 41% to $236.3M, Institutional segment decrease of 7% to $314.2M. Net income also reflects General and administrative increase from $26.3M to $76.1M (expense), Selling and marketing increase of 76% to $25.5M (expense).
Employees: 645 as of Feb 1, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $453.29M as of Sep 30, 2022
Annual revenue (TTM): $802.94M as of Sep 30, 2022
EBITDA (TTM): $395.32M as of Sep 30, 2022
Net annual income (TTM): $271.57M as of Sep 30, 2022
Free cash flow (TTM): $277.33M as of Sep 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 29,438,052 as of Nov 1, 2022
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.